Kelly Gordon

Kelly Gordon, PhD, MB(ASCP), RAC-Devices is the Founder and CEO of Boudicca Dx., LLC, a precision medicine consulting firm established in October 2015 that accelerates global precision medicine product development. In addition to leading Boudicca Dx., Kelly serves on the Scientific Advisory Boards for Proteotype Diagnostics and Cellens Inc., providing expertise in disease monitoring and mechanobiology, respectively. Previous roles include leadership positions at Loxo Oncology, HTG Molecular Diagnostics, and Ventana Medical Systems, focusing on companion diagnostics and regulatory strategies. Educational achievements include a PhD in Pharmacology from Duke University and postdoctoral training in Cancer Biology.